Genetic testing rates, practices and trends for ovarian cancer patients in the PARP inhibitor era

被引：0
|
作者：
Folsom, Susan [1 ]
O'Brien, Emily [1 ]
Narayan, Jeyani [2 ]
McGough, Christine [1 ]
Lesnock, Jamie [1 ]
Sukumvanich, Paniti [1 ]
Rush, Shannon [1 ]
Berger, Jessica [1 ]
Courtney-Brooks, Madeleine [1 ]
Taylor, Sarah [1 ]
机构：
[1] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2158
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [1] RATES OF GENETIC TESTING IN HIGH GRADE SEROUS OVARIAN CANCER PATIENTS IN THE ERA OF PARP INHIBITOR THERAPY: A POPULATIONBASED STUDY
    Brent, Shannon
    Mcgee, Jacob
    Vicus, Danielle
    Kim, Raymond
    Eisen, Andrea
    Yu, Winnie
    Wilton, Drew
    Gien, Lilian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A132 - A132
  • [2] Rates of genetic consultation in high-grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population-based study
    Brent, Shannon E.
    McGee, Jacob
    Vicus, Danielle
    Kim, Raymond
    Eisen, Andrea
    Wilton, Andrew S.
    Gien, Lilian T.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 166 (01) : 282 - 289
  • [3] Ovarian Cancer and PARP Inhibitor: Oncological Genetic Pathway of Female Patients
    Blin, J.
    Nowak, F.
    ONCOLOGIE, 2017, 19 (5-6) : 191 - 198
  • [4] Assessment of genetic testing rates in ovarian cancer patients
    Alzamora, M. C.
    Sia, T. Y.
    Tergas, A. I.
    Hou, J. Y.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 266 - 266
  • [5] Information practices around genetic testing for ovarian cancer patients
    Trace, Ciaran B.
    Zhang, Yan
    Yi, Siqi
    Williams-Brown, Marian Yvette
    JOURNAL OF THE ASSOCIATION FOR INFORMATION SCIENCE AND TECHNOLOGY, 2023, 74 (11) : 1265 - 1281
  • [6] Current practices on genetic testing in ovarian cancer
    Fostira, Florentia
    Papadimitriou, Marios
    Papadimitriou, Christos
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [7] Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients
    Carballo, Erica, V
    Kim, Kenneth H.
    Penn, Courtney A.
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 204 - 211
  • [8] Impact of PARP inhibitor expanded access program on the uptake of genetic testing in newly diagnosed or recurrent ovarian cancer patients in Singapore
    Ong, P. Y.
    Tan, D. S.
    Aung, K. Z.
    Er, J. B. T.
    Lee, S. C.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 76 - 77
  • [9] PARP inhibitor nanotherapy for ovarian cancer
    Baldwin, Paige
    Ohman, Anders
    Thong, Jeremy
    Tangutoori, Shifalika
    Dinulescu, Daniela
    Sridhar, Srinivas
    CLINICAL CANCER RESEARCH, 2016, 22
  • [10] Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
    Fumagalli, Caterina
    Tomao, Federica
    Betella, Ilaria
    Rappa, Alessandra
    Calvello, Mariarosaria
    Bonanni, Bernardo
    Bernard, Loris
    Peccatori, Fedro
    Colombo, Nicoletta
    Viale, Giuseppe
    Barberis, Massimo
    Guerini-Rocco, Elena
    CANCERS, 2019, 11 (11)
12345